Aster DM Healthcare Limited announced a strategic move to consolidate its ownership in material subsidiary Malabar Institute of Medical Sciences Limited (MIMS) through the acquisition of additional equity shares. The company's Investment and Finance Committee approved this proposal during its meeting held on January 29, 2026.

Acquisition Structure and Shareholding Consolidation

The proposed acquisition is designed to increase Aster DM Healthcare's shareholding in MIMS from the current 79.75% to 100%. The transaction involves purchasing an aggregate 20.25% of MIMS's equity share capital from existing shareholders through a structured letter of offer.

Transaction Timeline and Process

The acquisition process will commence with the dispatch of a letter of offer to MIMS shareholders, with the company estimating transaction completion within three months from the offer dispatch date. The actual number of shares to be purchased depends on the acceptance and participation of existing shareholders in the offer.

MIMS Financial Performance and Background

Malabar Institute of Medical Sciences Limited, established on February 17, 1995, operates in the healthcare services sector with a focus on hospital operations. The company is registered in Govindapuram P.O., Calicut, Kozhikode, Kerala, and operates exclusively within India.

As of March 31, 2025, MIMS reported a turnover of INR 1,118.05 crores and achieved a profit of INR 134.51 crores, demonstrating consistent growth in its healthcare operations.

Regulatory Compliance and Related Party Considerations

The proposed acquisition will not be classified as a related party transaction, as neither the promoters, promoter group, nor any group companies have interest in the entity being acquired. The transaction does not require specific governmental or regulatory approvals, streamlining the acquisition process.

Strategic Impact

This consolidation move aligns with Aster DM Healthcare's strategy to strengthen its control over key healthcare assets. The acquisition will provide complete ownership of MIMS, enhancing operational control and strategic decision-making capabilities within the healthcare services segment.

Aster DM Healthcare has formally announced its earnings conference call scheduled for February 02, 2026, at 11:00 AM IST to discuss the company's unaudited financial results for the quarter and nine months ended December 31, 2025. The announcement was communicated to both BSE Limited and the National Stock Exchange of India Ltd on January 27, 2026, in compliance with regulatory requirements.

Regulatory Compliance and Communication

The earnings call announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary and Compliance Officer Hemish Purushottam signed the official communication, ensuring proper adherence to disclosure norms for listed companies.

Management Participation

The Q3FY26 earnings conference call will feature comprehensive representation from Aster DM Healthcare 's senior management team. The following executives will participate in the call:

Call Details and Access Information

The earnings conference call is specifically designed for analysts and investors to gain insights into the company's financial performance for Q3FY26. The call will provide detailed discussions on the unaudited financial results covering both quarterly and nine-month periods ended December 31, 2025.

Corporate Information

Aster DM Healthcare operates from multiple locations with its registered office located at No 7-1-450/20, Plot No-04, Mythri Vihar, Sanjeev Reddy Nagar, Hyderabad, Ameerpet, Telangana, India - 500038. The company's corporate office is situated at Awfis, 2nd Floor, Renaissance Centra, 27 & 27/1, Mission Road, Sampangi Rama Nagar, Bengaluru, Karnataka, India - 560027.

For additional clarification regarding the earnings call, interested parties can reach out via email to investors@asterdmhealthcare.in . The company has established this dedicated communication channel to address investor queries and provide necessary support for call participation.